In a recent interview with Stockhead, Dr. Camile Farah, CEO and Managing Director of Optiscan (ASX: OIL), discussed the company’s latest breakthrough—the Inform digital pathology device.

Optiscan’s first-in-class digital imaging technology is designed to bring pathology into the digital era, enabling instant microscopic imaging at the point of tissue collection. By eliminating the traditional 24-48 hour lab processing delay, Inform allows pathologists to assess samples in real-time, delivering faster results to doctors and patients.

Optiscan is currently working through the FDA regulatory pathway in the U.S., collecting clinical data to support its imaging claims and expand its reach in hospitals and pathology labs.

Watch the interview to learn more about Optiscan’s innovative technology, U.S. expansion, and insights from Dr. Farah.

Watch the full interview in The Australian here. 

Watch the full interview on Stockhead here.